Faron Pharmaceuticals, Pharmbio Korea deal

Faron granted Pharmbio exclusive, Korean rights to develop and commercialize Traumakine in exchange for EUR750,000 ($850,050) and undisclosed development milestones. Pharmbio will also pay Faron one-...